Global Access and Impact: Closing the Gaps Schedule

Global Access to Immunotherapy: Closing the Gaps

Workshop Agenda

Dec. 9–10, 2020

Enduring Materials from the Workshop are accessible on this page. Please click on the links below to access presentation slides and video.

If you have questions about "Global Access to Cancer Immunotherapy: Closing the Gaps" enduring materials, please contact fdewalt@sitcancer.org.

SITC is committed to sharing presentations from its programs for the advancement of the field but respects faculty requests to maintain confidentiality of their unpublished data and therefore will be unable to share presentations with this symbol

Return to

Global Access and Impact Homepage

2020 Workshop Homepage

Schedule

Wednesday, Dec. 9, 2020

9:00 – 9:20 a.m.	Welcome David Kaufman MD, PhD – Third Rock Ventures Samir Khleif, MD – Georgetown University
Session 1: Setting the Stage
9:20 – 9:40 a.m.	African access initiative insights: the promise, potential, and implications of cancer immunotherapies in Africa Jennifer Dent, MBA – BIO Ventures for Global Health
9:40 – 10:00 a.m.	Barriers and opportunities for cancer immunotherapy in Africa Nestory Masalu, MD – Bugando Medical Center
10:00 – 10:20 a.m.	Access to immunotherapy in Mexico: Mission impossible? Nora Sobrevilla-Moreno, MD – Instituto Nacional de Cancerología
10:20 – 10:50 a.m.	Panel discussion Moderator: Olufunmilayo Olopade, MD, FACP – University of Chicago Panelists: Jennifer Dent, MBA – BIO Ventures for Global Health Nestory Masalu, MD – Bugando Medical Center Nora Sobrevilla-Moreno, MD – Instituto Nacional de Cancerología Clarissa Mathias , MD, PhD – NOB/Oncoclínicas
10:50 – 11:00 a.m.	Break
Session 2: Challenges to Global Immunotherapy Access
11:00 – 11:20 a.m.	Capacity considerations for innovative cancer medicines Marko Spasic, MD – Parker Institute for Cancer Immunotherapy
11:20 – 11:40 a.m.	Innovation in cancer care in sub-Saharan Africa: a phase I study of rituximab hyalronidase at the Uganda Cancer Institute Thomas Uldrick, MD, MS – Fred Hutchinson Cancer Research Center
11:40 – 12:00 p.m.	Immuno-oncology research in Central Eastern Europe – population access and site readiness for immunotherapy Anna Baran, MD – KCR Consulting Yaroslav Shparyk, MD, phD – Lviv State Oncological Regional Medical and Diagnostic Center
12:00 - 1:00 p.m.	Panel discussion Moderator: Taofeek Owonikoko, MD, PhD, MSCR – Emory University Panelists: Marko Spasic, MD – Parker Institute for Cancer Immunotherapy Thomas Uldrick, MD, MS – Fred Hutchinson Cancer Research Center Anna Baran, MD – KCR Consulting Oscar Arrieta, MD, MS – Instituto Nacional de Cancerología Muhammad Habeebu – NSIA-LUTH Cancer Centre/University of Lagos Alicia van der Laat, MD – Hospital Mexico, Costa Rica Yaroslav Shparyk, MD, PhD – Lviv State Oncological Regional Medical and Diagnostic Center
1:00 p.m.	Day 1 Closing remarks David Kaufman, MD, PhD – Third Rock Ventures

Thursday, Dec. 10, 2020

Session 3: Vision for Products with Impact and Sustainable Access
9:00 – 9:30 a.m.	Round Table: PD-1 checkpoint therapies from China: local experience and plans for emerging markets Moderator: Wenru Song, MD, PhD – Kira Pharma Panelists: Shirley Zhao – CStone Pharmaceuticals Yong Ben, MD, MBA – BeiGene Sheng Yao, MD – Shanghai Junshi Biosciences Co.
9:30 – 9:50 a.m.	Barriers and approaches to cancer immunotherapy in LMICs Ute Dugan, MD, PhD – Parker Institute for Cancer Immunotherapy Phangisile Mtshali – Bristol-Myers Squibb Foundation
9:50 – 10:10 a.m.	Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in HPV–associated malignancies Claudia-Nanette Gann, MD – EMD Serono
10:10 – 10:30 a.m.	Roche perspective on global access to cancer therapies, including I-O Frank Loeffler – Roche Philip Anderson, MD – Roche
10:30 – 10:50 a.m.	Panel discussion Moderator: Phangisile Mtshali – Bristol-Myers Squibb Foundation Panelists: Ute Dugan, MD, PhD – Parker Institute for Cancer Immunotherapy Claudia-Nanette Gann, MD – EMD Serono Frank Loeffler – Roche Philip Anderson, MD – Roche
10:50 – 11:00 a.m.	Break
Session 4: Scientific Questions That Need to be Answered in LMIC’s
11:00 – 11:20 a.m.	Presentation and survival from breast cancer in SSA Nixon Niyonzima, MD – Uganda Cancer Institute
11:20 – 11:40 a.m.	Evaluation of immune checkpoint inhibitors in medically vulnerable populations: challenges and opportunities for translational research Elad Sharon, MD, MPH – National Cancer Institute
11:40 – 12:00 p.m.	Cervical cancer and checkpoint blockade Alfonso Dueñas – Instituto Nacional de Cancerología
12:00 - 12:20 p.m.	Panel discussion Moderator: Verna Vanderpuye, MD – Bu Teaching Hospital Panelists: Ramya Ramaswami, MBBS, MPH – National Cancer Institute Elad Sharon, MD, MPH – National Cancer Institute Nixon Niyonzima, MD – Uganda Cancer Institute Alfonso Dueñas – Instituto Nacional de Cancerología Adedayo Joseph, MD – NSIA-LUTH Cancer Center Thomas Uldrick, MD, MS – Fred Hutchinson Cancer Research Center
Session 5: Wrap-up: Next Steps and Line of Sight to Recommendations
12:20 - 12:40 p.m.	Accelerating access to cancer immunotherapies: Learning from the global health experience of CHAI, American Cancer Society, and Allied Against Cancer Emily Kobayashi – Clinton Health Access Initiative
12:40 - 1:00 p.m	Round Table: Networking to increase cooperation between regions: Clinical trials, sharing of epidemiologic data, and other areas for collaboration Moderator: Nora Sobrevilla-Moreno, MD – Instituto Nacional de Cancerología Panelists: Marisa Nimrod, MD – Caribbean Association of Hematology and Oncology Hanna Simonds, MBChB, MRCP, FRCR – Stellenbosch University Oscar Arrieta, MD, MS – Instituto Nacional de Cancerología Addu Bounedja – Saad Dahlab University
1:00 - 1:25 p.m.	Panel discussion Moderator: Fredrick Chite Asirwa, MD – International Cancer Institute Eldoret Panelists: Satish Gopal, MD, MPH – National Cancer Institute David Kaufman, MD, PhD – Third Rock Ventures Samir Khleif, MD – Georgetown University Verna Vanderpuye, MD – Bu Teaching Hospital Nora Sobrevilla-Moreno, MD – Instituto Nacional de Cancerología Tolulope Adewole, MBBS – NSIA-LUTH Cancer Center Zainab Mohamed, MBChB, MMed – University of Cape Town Ute Dugan, MD, PhD – Parker Institute for Cancer Immunotherapy
1:25 - 1:30 p.m.	Conclusion and thank you David Kaufman, MD, PhD – Third Rock Ventures